Trial reportActa neuropsychiatrica2026
Aspirin and atorvastatin augmentation treatment in patients with major affective disorders and inflammatory dysregulation: a 12-week randomised Placebo-controlled study.
Trial report in Acta neuropsychiatrica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated whether aspirin and atorvastatin provide additional antidepressant effects in patients with major affective disorders and inflammatory dysregulation.
methodsThree 12-week treatment groups, each receiving aspirin (100 mg/day), atorvastatin (10 mg/day), or a placebo, were randomly assigned to 14 patients (seven with major depressive disorder [MDD] and seven with bipolar disorder [BD]), as well as two additional groups of 17 patients (each with nine patients with MDD and eight patients with BD). All patients had Clinical Global Impressions scores ≤3 and met the criteria for inflammatory dysregulation (i.e., C-reactive protein (CRP) level ≥ 1,000 ng/ml or soluble tumour necrosis factor-α receptor 1 (TNF-αR1) level ≥ 800 pg/ml). The Hamilton Depression Rating Scale (HDRS) and Montgomery-Sberg Depression Rating Scale (MADRS) were used to assess depressive symptoms, and the Global Assessment of Functioning Scale (GAF) was used to assess overall functioning. Baseline and week 12 CRP, TNF-αR1, and soluble IL-2 receptor (sIL-2R) levels were evaluated.
resultsGeneralised estimating equation models demonstrated a reduction in total HDRS (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.